Reversible Effects of Integrase Inhibitors on Newly Differentiated Adipocytes

Documenti analoghi

• Cardiometabolic Differences in People Living with HIV Receiving Integrase Strand Transfer Inhibitors Compared to Non-nucleoside Reverse Transcriptase Inhibitors: Implications for Current ART Strategies
  di: Wilhelm A. J. W. Vos, et al.
  Pubblicazione: (2024-04-01)
• Spectrum of Non-Nucleoside Reverse Transcriptase Inhibitor-Associated Drug Resistance Mutations in Persons Living with HIV-1 Receiving Rilpivirine
  di: Pavithra Nagarajan, et al.
  Pubblicazione: (2024-10-01)
• Predictive Efficacy of Dual Therapies Combining Integrase Strand Transfer Inhibitors with Second-Generation Non-Nucleoside Reverse Transcriptase Inhibitors Following HIV-1 Treatment Failure in Cameroon: Implications for the Use of a Long-Acting Therapeutic Strategy in Low- and Middle-Income Countries
  di: Davy-Hyacinthe Gouissi Anguechia, et al.
  Pubblicazione: (2024-11-01)
• Revisiting efavirenz in the era of dolutegravir: Low-dose efavirenz, a viable alternative capable of holding its own against dolutegravir-based regimens
  di: Sumit Arora, et al.
  Pubblicazione: (2023-01-01)
• Nucleoside Reverse Transcriptase Inhibitor Exposure Is Associated with Lower Alzheimer’s Disease Risk: A Retrospective Cohort Proof-of-Concept Study
  di: Tiffany W. Chow, et al.
  Pubblicazione: (2024-03-01)